FindTrial
Sign In

Moderna mRNA-1273

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), COVID-19 Prevention Network

Conditions

COVID-19HIV InfectionsJuvenile Dermatomyositis (JDM)Juvenile Idiopathic Arthritis (JIA)Multiple Sclerosis (MS)Pediatric SLEPediatric-Onset Multiple Sclerosis (POMS)Pemphigus Vulgaris

Phase 2

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
TerminatedNCT05000216
National Institute of Allergy and Infectious Diseases (NIAID)Juvenile Dermatomyositis (JDM), Juvenile Idiopathic Arthritis (JIA), Multiple Sclerosis (MS) +6
Start: 2021-08-13End: 2024-03-28Updated: 2025-08-22
Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern
CompletedNCT05168813
COVID-19 Prevention NetworkCOVID-19, HIV Infections, SARS-CoV-2 Infection
Start: 2021-12-01End: 2024-04-19Updated: 2025-11-26

Related Papers

Prospective SARS-CoV-2 additional vaccination in immunosuppressant-treated individuals with autoimmune diseases in a randomized controlled trial.
2025-11-251 citations
Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIV
UNC Libraries2025-10-16
Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIV.
2025-10-062 citations
Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) study.
2025-01-205 citations